Table 3 The analysis of the adverse events in all studies.

From: Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials

Adverse events (AEs)

Studies No

I/C

For SCT arm

I/C

For control

Model

Effect of estimate, RR, 95% CI

P value

Heterogeneity, I2% (p value)

Serious AEs

6

9/150

12/122

RE

0.64 [0.16, 2.58]

0.53

41.95% (p = 0.13)

Administration-related AES

2

19/81

6/79

RE

2.55 [1.08, 6.03]

0.034

0% (P = 0.6)

Headache

2

14/44

8/20

RE

0.79 [0.41, 1.5]

0.47

0% (P = 0.53)

Total infections

3

22/110

38/103

RE

0.58 [0.37, 0.9]

0.02

0% (P = 0.44)

Gastrointestinal disorders

3

18/83

10/91

RE

1.72 [0.37, 7.87]

0.49

69.63% (p = 0.04)

Blood and lymphatic system disorders

3

12/130

8/138

RE

1.75 [0.59, 5.14]

0.31

25.83% (P = 0.26)

  1. CI confidence interval, RE random effects.
Back to article page